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Abstract
The Institute of Medicine’s publications To Error is Human and Crossing the Quality Chasm 
publicized the widespread deficits in U.S. health care quality. Emerging studies continue to reveal 
deficits in the quality of adult and pediatric care, including subspecialty care. In recent years, key 
stakeholders in the health care system including providers, purchasers, and the public have been 
applying various quality improvement methods to address these concerns. Lessons learned from 
these efforts in other pediatric conditions, including asthma, cystic fibrosis, neonatal intensive 
care, and liver transplantation may be applicable to the care of children with inflammatory bowel 
disease.
This review is intended to be a primer on the quality of care movement in the United States, with a 
focus on pediatric inflammatory bowel disease. In this article, we review the history, rationale, and 
methods of quality measurement and improvement, and we discuss the unique challenges in 
adapting these general strategies to pediatric IBD care.
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A. Introduction
The quality of health care in the United States has received considerable attention in both 
scientific journals and the lay press in recent years. There is now abundant evidence that the 
U.S. health care system is facing a widespread quality problem, involving nearly every 
aspect of medical care including pediatric inflammatory bowel disease (IBD). Fortunately, a 
number of quality improvement strategies have been developed and applied over the last 
several decades, and lessons learned in other medical specialties may be applicable to 
pediatric IBD including Crohn’s disease (CD), ulcerative colitis (UC), and inflammatory 
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bowel disease unspecified (IBDU). The objectives of this article are 1) to provide an 
overview of quality of care research in the United States, 2) to review examples of quality 
measurement and improvement from the pediatric literature, 3) to underscore the need for 
quality improvement (QI) in inflammatory bowel disease, and 4) to discuss specific issues 
related to pediatric IBD quality improvement and review the early work in this area..
B. Overview of Quality of Care in the United States
Early History
While the topic of health care quality has received significant attention in recent years, the 
concept of measuring and improving the quality of care began over one-hundred years ago 
with the American College of Surgeons (ACS) employment of Earnest Codman’s “end-
result system” [1] to track patient outcomes. The ACS was later joined by the American 
College of Physicians (ACP), the American Hospital Association (AHA), the American 
Medical Association (AMA), and the Canadian Medical Association (CMA) to form the 
Joint Commission on the Accreditation of Hospitals in 1951. Since then, the quality of care 
movement in the United States has grown and evolved.
Principles of Quality Measurement
Avedis Donabedian, one of the founding fathers of the quality of care movement, outlined a 
framework for measuring quality of care along three dimensions—Structure, Process, and 
Outcomes [2] (Table 1). Structural Measures are characteristics of the setting in which care 
is delivered (nurse/patient ratio, use of electronic medical record system, practice type, level 
of accreditation). Process Measures, largely developed from evidence-based practices, 
indicate the steps taken by health care providers in the care of an individual patient (timely 
prescription of medications, ordering appropriate screening exams). Outcome Measures 
indicate what happens to patients as the result of an intervention (disease activity, quality of 
life, etc.).
Though outcome measures have the most intrinsic value, numerous factors complicate their 
use. First, factors outside the control of the health care provider (e.g. disease severity, 
comorbidity, socioeconomic factors, adherence) contribute to patient outcomes. Although 
the process of "risk-adjustment" attempts to take many of these factors into account, it is an 
imperfect science. Thus, the relationship between process measures (i.e. doing the right 
thing) and outcome measures (i.e. having the desired result) is not always linear. A second 
limitation to outcome measures is that disease outcomes may not occur until several years 
after treatment has begun. This is especially true for a chronic illness such as IBD, creating 
difficulty in studying and measuring quality of care.
Consequently, process measures have been the most widely-studied quality measure. They 
are more sensitive [3], more responsive to change, more accepted by physician groups, and 
more resistant to bias from imperfect risk-adjustment strategies (if exceptions are allowed 
for contraindications such as co-morbidities). However, if process measures are to be 
meaningful, strong evidence linking clinical processes to improved health outcomes is 
necessary. Thus, the use of process measures for conditions such as pediatric IBD, for which 
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broadly applicable, evidence-based practices are few and clinical practice guidelines do not 
exist, is challenging.
Pioneering Studies
The 1970’s work of John Wennberg and Alan Gittelsohn kindled the quality of care 
movement by demonstrating small-area variations in the utilization of health services and 
associated expenditures.. Variation in care has the potential to affect quality when it results 
in underuse, overuse, or misuse of diagnostic and therapeutic interventions, and is frequently 
cited as a marker for "serious and widespread quality problems" (Table 2) [4] [5]. In 
performance variation, a difference exists between what is considered optimal performance 
and observed performance [6] [7]. Several studies in the mid-1990’s demonstrated that 
beneficial therapies were often withheld [8], risky or unnecessary therapies were given [9], 
[10], or preventable complications/mortality were experienced by an unacceptable number 
of American patients [11, 12]. Prominent examples include the publication of hospital 
mortality rates by the Health Care Financing Administration (Medicare predecessor) in 
1986–1991 [13] and of coronary artery bypass surgery outcomes by the New York State 
Department of Health in 1989 [14].
Institute of Medicine Reports
In the years 2000 and 2001, the Institute of Medicine published two reports,To Err is 
Human[15] andCrossing the Quality Chasm[16], which thrust quality of care into the 
public eye and resulted in public demand for accountability from the health care profession. 
In 1990, the IOM defined quality of care as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge.” [17] Over a decade later, the Institute of 
Medicine's Committee on Quality of Health Care in America found "strong evidence" that 
Americans were not receiving health care that was based on the best available scientific 
knowledge [4]. To Err is Human, reported that "tens of thousands of Americans die each 
year from errors in their care, and hundreds of thousands suffer or barely escape non-fatal 
injuries". Fifteen months later, the Crossing the Quality Chasm report concluded that 
"between the health care we have and the care we could have lies not just a gap, but a 
chasm." The IOM reports were a call to action—implying that quality can be defined, should 
be measured, and that the entire health care system must be involved to substantially 
improve care.
Further evidence of the quality chasm
Many subsequent studies published over the last five years have reinforced the findings of 
the IOM reports. McGlynn and colleagues, in a large study of outpatient quality of care, 
demonstrated that adults receive only 54.9% of recommended care [18]. Unexpectedly, they 
found little racial and socio-economic disparities in the provision of care: all groups 
experienced deficient care at essentially the same rate [19]. Children faired worse than 
adults, receiving only 41% of preventive services and 53% of recommended vaccinations 
[20]. Inpatient care also has quality deficits. In a study of 10 widely-accepted hospital 
quality indicators for acute myocardial infarction, congestive heart failure, and pneumonia, 
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Jha et al observed that the quality of hospital care in the United States varies widely across 
different quality indicators [21]. Numerous additional studies have echoed these findings of 
on-going deficiencies in inpatient and outpatient care [22] [23] [24].
Key Stakeholders
Several key stakeholders, each with a vested interest in improving the quality of care 
delivered to Americans, have emerged in response to these reports of deficits in health care 
quality. These stakeholders include: 1) government and other regulatory bodies, 2) 
foundations, 3) patients, 4) payers (Medicare, Medicaid, and commercial insurers), and 5) 
providers (physicians, hospitals, etc.) Understanding their roles and perspectives helps to 
shed light on some of the drivers of the quality of care movement.
Governments and Foundations: “Determined Leaders”—Preceding the IOM 
reports, the US Government’s Department of Health and Human Services made quality a 
priority in 1989, with the establishment of the Agency for Health Care Policy and Research. 
Later renamed the Agency for Healthcare Research and Quality (AHRQ), its mission 
includes promoting high scientific standards for quality improvement and patient safety, 
outcomes and clinical effectiveness research, clinical practice and technology assessment, 
and the study of health care organization, delivery systems, and financing [25]. Furthermore, 
the Center for Medicare and Medicaid Services (CMS) has been on the leading edge of 
quality improvement since the 1970's, promoting transparency in health care reporting and 
adoption of novel health-care financing strategies. In addition to government involvement, 
many private foundations and business collectives have also added force to the healthcare 
quality revolution, each unique in its scope and goals but with the welfare of the patient in 
mind.
Patients & payers: "Motivated Consumers"—Many patients receive health care 
access through employer-provided health insurance. Concerns with escalating costs and 
gross medical errors have motivated patients and insurers to speak out against gaps in the 
healthcare system. Together, employers, patients, and insurance companies are one of the 
largest “purchasers” of health care and have become a formidable bargaining collective, 
demanding both accountability and value for their product. Patients want the highest quality 
care; however, insurers are reluctant to pay for expensive care unless it is effective. An 
emerging concept is “value based purchasing” [26], where interventions are ranked and 
reimbursed according to cost and effectiveness. Insurers have also begun to develop their 
own measures and rewards of quality, including designating “preferred providers” and 
publicly ranking hospitals based on quality indicators. A notable exception at the present 
time is the treatment of rare diseases, including pediatric IBD, for which limited clinical 
evidence precludes these standardized approaches.
Providers: “Reluctant Partners”—Physicians have often approached the subject of 
quality of care with a mixture of “anger, skepticism, or simply disinterest” [27] due to 
concerns with the validity, reliability, and accuracy of quality measurement [27] [28]. There 
is also the fear that quality assurance measures are “disguised … efforts to control costs 
rather than improve quality” [29] [28] [30]. However, physician groups are now realizing 
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that active participation is required to ensure valid, systematic application of quality 
measurement. For example, in 2004, the American Academy of Family Physicians (AAFP) 
and the American College of Physicians (ACP) joined the commercial insurers of America’s 
Health Insurance Plans (AHIP) and the Agency for Healthcare Research and Quality 
(AHRQ) to form the Ambulatory Quality Care Alliance. Similarly, the American Medical 
Association has created the Performance Improvement Collaborative partnering physician 
specialty organizations with experts in methodology and data collection to create 
performance measures for the CMS’s Physician Quality Reporting Initiative (PQRI) [31]. 
The American Academy of Pediatrics, has also established its own quality improvement 
infrastructure to address quality issue specific to pediatric disease.
Approaches to Quality Improvement
Approaches to quality improvement are varied in scope, design, and target. Ranging from 
simple to complex, they target health services delivery at multiple points along the process 
of care. The following paragraphs review several of the commonly used QI methods.
The chronic care model—In its Crossing the Quality Chasm report, the IOM concluded 
that "the changes needed to realize a substantial improvement in health care involve the 
health care system as a whole". Re-designing delivery systems to support coordinated, 
multidisciplinary chronic illness care is a major component of this change. The chronic care 
model is a proposed framework for such delivery system changes [32]. This model posits 
that improved patient outcomes result from carefully designed systems of care that include 
patient and family self-management support, delivery system design, decision support, and 
clinical information systems working in concert with the greater health care organization 
and community resources (Figure 1). Self-management support emphasizes the patient’s 
central role in managing their health, utilizing motivational interviewing, goal-setting, action 
planning and problem solving. The delivery system design component involves defining 
roles and distributing tasks among the medical team, using planned interactions to support 
evidence-based care, and ensuring regular follow up. Decision support embeds evidence-
based guidelines into daily clinical practice. Clinical information systems 1) provide timely 
reminders for needed services, 2) summarize data to track and plan care, 3) identify groups 
of patients needing additional care, and 4) facilitate performance monitoring. Incorporation 
of these chronic care model components encourages productive interactions between 
informed, activated patients and prepared, pro-active practice teams. Not surprisingly, 
interventions designed with this framework have resulted in improved outcomes in a number 
of pediatric [33] and adult chronic conditions [25].
Improvement collaboratives—Quality improvement collaboratives have emerged as a 
widely endorsed approach to organizing improvement efforts at hospitals and/or ambulatory 
practices. [34] These collaboratives date back to the mid-1980s, with some of the earliest 
and most successful examples including the Northern New England Cardiovascular Disease 
Study Group, the US Veterans’ Affairs National Surgical Quality Improvement Program, 
and the Vermont Oxford Network. These ongoing initiatives have improved care and saved 
many lives [35] [36] [37]. Improvement collaboratives bring together multidisciplinary 
teams from multiple sites focusing on a common problem. Experts in clinical and 
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performance improvement provide the group with training in quality improvement methods. 
Teams review the evidence for recommended care practices, set measurable targets, track 
their performance and receive feedback, study effective changes from other sites, and adapt 
and expand these changes at their own centers. Although this model has considerable face 
validity and has been popularized by the Institute for Healthcare Improvement and similar 
organizations, the evidence to support their widespread use remains limited and the impact 
on outcomes has been moderate, at best [38].
Health Information Technology (HIT)—Adoption of HIT is a major priority for 
healthcare leaders [4, 7, 16]. The Crossing the Quality Chasm report underscored the 
importance of improving the information technology infrastructure, and HIT has been 
incorporated into the CMS Quality Roadmap [39]. Examples of HIT QI interventions 
include computerized order entry [40, 41] [42] [43], clinical decision support systems [44] 
[45], automated patient and physician reminder systems [46], chronic disease management 
tools [47], telemedicine [48], and electronic health records [49] [50].
In 2005, Garg and colleagues published a review of computerized decision support tools 
[44]. They examined 100 randomized and non-randomized trials where a control group was 
employed, including systems for diagnosis, disease management, reminders for preventive 
services, drug dosing and prescribing. A significant proportion of the trials showed 
statistical improvement in provider performance; however, improvement in patient 
outcomes remained marginal. Another example of HIT is the use of automated provider 
reminders for childhood vaccination [51]. In a non-randomized trial, automated reminders 
were associated with significant improvements in captured immunization opportunities at 
sick visits (from 11.3% to 32.0%) but only modest improvements at well visits (from 78.2% 
to 90.3%).
Although the concept of using HIT to improve health care is appealing, the effectiveness of 
such interventions is difficult to evaluate due to methodological concerns (i.e. small sample 
size, contamination bias from non-randomized designs [49], and the concern for publication 
bias [46]), and the strong public pressure to rapidly adopt HIT without rigorous study.
Report Cards and Pay for Performance—Report cards and Pay for Performance 
(P4P) are two related quality improvement strategies that have been recently promoted [52] 
[53] [54]. Report cards, also known as “peer-comparison feedback” [55], provide physicians 
with a direct comparison of their performance relative to their peers. P4P is a financial 
incentive strategy linking performance to reimbursement. Advocates of reports cards and 
P4P hope to promote transparency in the health care system, empower patients to make 
more informed healthcare choices, and provide a mechanism to reimburse physicians for 
providing quality care.
The CMS, private foundations, health care leaders, and payers quickly embraced report 
cards and P4P, hoping that identifying and reimbursing high-performance could resolve the 
tension between cost, quality, and effectiveness [30] [7] [56]. To date, the evidence for the 
effectiveness of report cards and P4P has been modest. Hannan et al analyzed the impact of 
New York State’s coronary artery bypass graft reporting and concluded that report cards had 
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reduced risk-adjusted mortality by 41% [14]; however, a meta-analysis of peer-comparison 
feedback interventions found a statistically significant but clinically unexceptional odds 
ratio of 1.091 (confidence interval 1.045 – 1.136) [57]. A systematic review of seventeen 
P4P interventions found that 13 of 17 demonstrated a partial or positive effect on some 
aspect of care, one demonstrated a negative effect, and four led to unintended consequences 
[58].
A number of additional concerns with report cards and P4P potentially limit their 
effectiveness. They have been criticized for providing incentives to avoid care for severely 
ill or complex patients [59] [7]. Physicians may be tempted to exaggerate the initial severity 
of their patients' condition to reap financial rewards for “miraculous” recoveries [60] or 
claim that an improvement in medical history documentation (immunization or tobacco use 
history) is an improvement in intervention (administering vaccines on schedule or promoting 
smoking cessation) [61] [62]. Finally, P4P and report cards have the potential to widen, or at 
least fail to correct pre-existing racial and ethnic disparities [52] [63]. Despite these 
criticisms of P4P and report cards, their popularity among the purchasers of health care and 
the lay public will likely ensure their place in quality improvement in the years to come. [64] 
[65] [30].
Industrial Approaches—A number of industrial quality improvement strategies, initially 
developed to monitor the manufacturing process have been adapted for use by the health 
care sector. The "model for improvement" stems from the work of Walter Shewart [6] and 
provides a framework for process improvement: (Figure 2) [66] [67]. First, time-sensitive 
and measurable aims are established, quantitative measures are developed to determine 
whether specific changes lead to improvement, and changes most likely to result in 
improvement are identified. These changes are then tested on a small scale using the Plan-
Do-Study-Act (PDSA) cycle—planning interventions, trying them, observing the results, 
and acting on what is learned. Successful changes are refined through several PDSA cycles, 
implemented on a broader scale, and spread to other parts of the organization or in other 
organizations.
C: Pediatric Health Care Quality and Quality Improvement: Lessons learned 
from general pediatricians and other subspecialists
As in adult populations, the pioneering work on quality of pediatric health care began with 
descriptions of variation in care. In 1989, Perrin et al described variation in the rates of 
discretionary, but not emergent, medical and surgical conditions in 3 geographic locations 
[68]. Since that time, a limited number of published reports suggest that quality problems 
are as widespread in pediatric care as in they are in adult care. Mangione-Smith et. al. 
examined hundreds of pediatric indicators of outpatient quality, including preventive care, 
care for acute conditions, and care for chronic conditions. According to data in the medical 
records, children in the study received 46.5% of the indicated care [20] consistent with prior 
studies of pediatric quality of care [69], as well as a recent report from the Commonwealth 
Fund [70]. These deficits provide a clear message that the current U.S. health care system is 
not meeting the needs of the pediatric population, including those with chronic conditions.
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Fortunately, a number of tools for measuring and improving pediatric chronic illness care 
have been developed by pediatric generalists and sub-specialists alike. Lessons learned from 
work in conditions such as asthma, cystic fibrosis, neonatal intensive care, and liver 
transplantation may serve as models for pediatric IBD.
Despite the availability of effective asthma medications, hospital admissions for this 
condition have been increasing over the last 20 years [71]. The underuse of effective 
controller therapy is a primary example of the quality gap in pediatric chronic illness [72]. In 
a recently published evaluation of an asthma improvement collaborative, the intervention 
group outperformed the control group in a number of process and outcome measures 
including peak flow monitoring, use of written action plans, and quality of life, yet no 
differences in the use of long-term controller medications were observed [73]. In a second 
collaborative which incorporated the concept of P4P, the percentage of patients receiving 
“perfect care” (controller medications and influenza vaccination) increased from 4% to 88% 
over a three year period [74]. This collaborative also demonstrated improvement in asthma 
outcomes including prevention of ED visits, hospitalizations, and missed school. Other QI 
interventions have been associated with reductions in oral steroid requirements [33] re-
admission rates [71], medication prescribing errors, and inpatient length of stay [75].
Cystic fibrosis (CF) is perhaps the best known example of pediatric quality improvement 
[76]. Since the 1960's, the CF Foundation has maintained a national patient registry 
containing demographic and clinical data on patients attending accredited CF care centers. 
This registry data has been used to raise awareness of center-based differences in both the 
process and outcomes of care. For example, in an observational study ranking CF centers on 
the basis of median FEV1, widespread differences in lung health were observed between 
centers. Notably, patients from higher ranking centers had more frequent monitoring of their 
clinical status, measurements of lung function, respiratory cultures, and use of intravenous 
antibiotics for pulmonary exacerbations [77]. Additional research revealed variation in the 
prevalence of nutritional failure (< 5th percentile for age) and life expectancy between 
centers that could not be explained by differences in case mix alone. Though the response to 
this data was mixed, most CF providers have accepted such variation as an opportunity to 
learn from high-performing centers to improve care at all centers [78] a process known as 
benchmarking [79]. Recognizing this, the CF Foundation has established an infrastructure to 
promote the development and spread of QI methods in the CF community. A number of QI 
collaboratives have been formed, based on the principles described above, and preliminary 
results have been encouraging [80] [81].
A third example of outstanding quality improvement in pediatric subspecialty care is the 
Vermont Oxford Neonatal Network (VON), a nonprofit organization of over 440 member 
neonatal intensive care units (NICUs) participating in a range of network activities 
(randomized controlled trials, outcomes research, and a variety of QI projects). VON 
maintains a database tracking the treatment and outcomes for high-risk infants receiving 
neonatal intensive care. The database provides members with quarterly and annual reports 
documenting performance and providing comparisons of each NICU with the entire VON 
network. These reports allow identification of opportunities for improvement and the 
tracking of changes over time. A series of QI collaboratives organized by the VON have 
Boyle et al. Page 8













resulted in improved outcomes, including reductions in the number of nosocomial 
infections, chronic lung disease, and overall healthcare costs. Internet-based QI 
collaboratives have continued and expanded upon these efforts [82].
A final example of pediatric QI involves the care children following liver transplantation. 
Therapeutic drug monitoring of calcineurin inhibitors in post-transplant patients is a key 
driver of graft survival. Yet, in a single-center study, Bucuvalas et al demonstrated that > 
50% of calcineurin inhibitor trough values were outside of the target range. Using the model 
for improvement discussed previously, a series of changes were tested including 1) 
developing consensus of target levels, 2) development of a protocol for therapeutic drug 
monitoring, 3) use of provider feedback through statistical process control charts, and 4) 
implementation of a protocol workflow sheet aligned with the protocol (decision support 
tool). These changes increased the proportion of trough levels within target range to 77% 
and reduced wide fluctuations of trough levels [83]. Work in pediatric liver transplantation 
also recognizes the need to expand outcome assessment beyond patient and graft survival, 
but also to quality of life years restored, resource utilization, and improved care delivery. 
Further understanding of these outcomes will help guide future research and care 
improvement initiatives [84].
D. Quality of care and quality improvement in pediatric inflammatory bowel 
diseases
Defining the need for improvement
Inflammatory bowel disease (IBD), including CD, ulcerative colitis and inflammatory bowel 
disease unspecified (IBDU), affects greater than 100,000 US patients less than 21 years of 
age [85]. The financial impact of IBD is substantial, with combined estimated adult and 
pediatric health care cost exceeding $1.7 billion annually [85]. Pediatric IBD also poses a 
unique social burden on children and their families, often at a time of fragile personal 
development during adolescence [86, 87]. Consequently, efforts to improve the clinical 
outcomes for these children are needed.
As with other chronic conditions, variation in care often is a signal that the health care 
system can improve (Table 2) and recognition of this variation is often the initial step in 
quality improvement. A small, but growing body of literature is beginning to demonstrate 
variation in the management of both adult and pediatric IBD. Ersrailian recently found 
extreme variation in adult provider opinion regarding treatment decision-making in CD, 
including the appropriateness of 5-ASA therapy, the use of immunomodulators and 
infliximab in perianal and fistulizing disease, and the indications for antibiotics in newly-
diagnosed and steroid-refractory CD [88]. This variation may be secondary to the wide 
range of available treatment options and paucity of broadly-applicable practice guidelines. 
Thus, it is no surprise that an adult study of IBD practice guideline implementation yielded 
only modest improvement in guideline use and thus reduced practice variation [89]. A recent 
qualitative study of adult gastroenterologists’ attitudes and practices assessed some of the 
drivers of IBD practice variation. The authors describe a number of themes that cluster 
around the belief that optimal treatment strategies for IBD have not been well defined and 
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that issues of disease variability and patient preference are not adequately captured by 
existing practice guidelines [90].
Although the lack of sufficient evidence on which to base treatment decisions may be one 
driver of practice variation, there are other examples of unwarranted variation resulting from 
underuse, overuse, or misuse of health care services. In a retrospective study of 67 adult 
patients referred to a tertiary care center, 64% of patients treated with 5ASA had received 
suboptimal dosing, 60% receiving chronic steroids had not attempted steroid-sparing 
medications, and 82% of those treated with steroid sparing regimens received suboptimal 
dosages. This study also found gaps in colorectal dysplasia surveillance and in screening/
treatment for osteopenia/osteoporois in patients treated with chronic steroids. Although this 
study may be limited by referral bias, the data presented reveals a quality gap in IBD care 
[91]. A subsequent study examined 6 quality indicators based on recently published 
guidelines from the British Society of Gastroenterology for adult IBD patients treated in 
general GI and IBD specialty clinics in London. Based on these process measures, the 
specialist IBD clinics provided higher quality care than the general gastroenterology clinics 
with regard to screening laboratory studies during immunosuppression initiation, bone 
protection at times of steroids use, and surveillance colonoscopy; however, gaps in 
performance were also noted in the specialist clinics [92]. Further quality deficits in care 
provided to IBD patients have been observed and continue to be evaluated in an ongoing, 
nationwide UK audit of inpatient and outpatient IBD management [93].
A recent analysis of data from the Pediatric IBD Collaborative Research Group, an ongoing 
inception cohort of children diagnosed with IBD, demonstrated substantial variation among 
centers in the initial treatment of CD. Such variation persisted, even after adjusting for 
potential confounders such as severity, age, and disease location [94]. As with other chronic 
illnesses, clearly a gap exists between ideal IBD care and actual patient care. Application of 
the principles of quality improvement discussed above, including measuring processes and 
outcomes of care, and designing and implementing interventions to improve the processes of 
care, will be an essential step in improving the outcomes for patients with IBD. Thus, it 
appears that clinicians caring for IBD patients are in a remarkably similar position to 
physicians who cared for critically ill neonates or CF patients one decade ago. Hence, there 
is a clear opportunity for collaborative learning and building new knowledge through the 
formation of networks that foster outcomes research, including studies of comparative 
efficacy and clinical effectiveness, and quality improvement.
Challenges to QI in pediatric IBD
As with other complex, chronic conditions with variable phenotypes and clinical 
progression, measuring and improving the quality of care in pediatric IBD is challenging on 
a number of levels. First, there is a lack of evidence to support best practices. Few 
randomized trials have been performed, studies of comparative efficacy are lacking, and the 
risk-benefit ratio of many therapies including thiopurines, methotrexate, and infliximab has 
not been adequately quantified. Thus, defining optimal care is near impossible. For these 
reasons, the North American Society for Pediatric Gastroenterology and Nutrition has not 
published IBD treatment guidelines, and other guidelines, while providing a framework for 
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medication use, do not precisely identify which patients to treat with which medications 
[95]. Therefore, defining evidence-based process measures is a significant challenge to 
quality measurement. However, this challenge is not insurmountable and a number of other 
aspects of IBD care might be amenable to the development of process measures including 
standardized assessment of growth, nutrition, and disease severity, preventative measures 
including influenza vaccination and opthomological examinations, and monitoring for 
medication toxicity (TB screening prior to infliximab, monitoring of complete blood count 
and liver enzymes while on immunomodulator therapy, etc.). Indeed, the selection of less 
controversial process measures has been well established in quality improvement programs 
for other chronic conditions (eg., annual lipid screening for diabetic patients).
A second challenge is the difficulty in selecting appropriate outcome measures. The ideal 
outcome measure would be clinically meaningful, easy to measure, applicable to all patients, 
and responsive to short-term changes. For these reasons the measurement of surrogate 
outcomes are widely used measures in other chronic conditions. Examples include a 
hemoglobin A1C in diabetes, or pulmonary function tests in cystic fibrosis. Unfortunately, 
no surrogate markers exist for IBD. Outcomes such as hospitalization are limited by the fact 
that indication for hospitalization is often subjective. The use of surgery as an outcome is 
similarly fraught with difficulty because, in many instances, surgery is an appropriate 
treatment (to avoid medication toxicity, to improve growth in ileal Crohn's, etc) rather than a 
negative outcome. Growth is an appealing outcome measure. Growth failure is a significant 
complication of pediatric IBD, may be correlated with disease activity, and thought to be 
amenable to medical, nutritional, or surgical interventions. However, the risk of growth 
failure may vary by disease type (CD versus UC), phenotype, and location, and thus may not 
be a good outcome measure for all patients. Furthermore, a number of practical issues 
complicating growth measurement include the difficulty in adjusting for pubertal stage and 
the need to exclude post-pubertal patients (a sizable proportion of pediatric IBD patients). 
Ultimately, measures of disease activity, quality of life, and other patient-centered outcomes 
may be the most appropriate for quality improvement purposes; however, the feasibility of 
measuring these outcomes in the context of routine clinical care will need to be addressed.
A related challenge is that the drivers of clinical outcomes are often multifactorial and thus 
may require more complex improvement strategies. For example, HIT interventions may be 
useful in preventing medication errors through automated drug interaction prompts, and 
improving health maintenance and immunization through automated reminders. However, 
improving disease activity and quality of life will likely require simultaneous attention to a 
number of areas including changing physician practice patterns, enhancing family self-
management, and promotion of medication adherence.
A third challenge in pediatric IBD quality improvement is that risk adjustment remains an 
imperfect science. The heterogeneity of pediatric CD and ulcerative colitis and the lack of 
reliable prognostic indicators at the present time make risk adjustment especially 
problematic. However, IBD physicians look forward to the day when clinical, genetic, 
immunological, and microbial markers will help to more precisely define clinical prognosis 
and, in turn, facilitate risk adjustment.
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Early improvement work and future directions
Given these challenges, pediatric IBD quality improvement can be a daunting task. 
Nevertheless, it appears that QI (along with basic, translational, and clinical research) is a 
necessary step to improve outcomes for patients with these conditions. Fortunately, 
momentum for pediatric IBD quality improvement is building. Increasing numbers of 
healthcare providers and IBD centers have started to discuss and begun to take actions to 
improve the care of their patients. Patients and families, many who have been inspired by 
widely publicized success in cystic fibrosis, are continuing to advance the quality dialogue 
and have volunteered considerable time serving on the advisory panels of several centers. A 
number of non-profit organizations have recently become engaged in pediatric IBD quality 
improvement. The North American Society for Pediatric Gastroenterology and Nutrition has 
formed a task force on quality improvement within the IBD committee, the Crohn's and 
Colitis Foundation of America has listed quality improvement as one of the challenges in 
pediatric IBD and has formed a Quality of Care Initiative, and the American 
Gastroenterological Association Task Force on Quality has identified CD as one of its key 
targets. Perhaps the most exciting step in pediatric IBD QI was the formation of the first 
quality improvement collaborative, the Pediatric Inflammatory Bowel Disease Network for 
Research and Improvement (PIBDNet) Trailblazer Collaborative in 2007. Preliminary 
results demonstrate improvement in a number of process measures, including the monitoring 
of growth and nutritional status [96]. This work is expected to lead to improvement in 
growth outcomes of affected patients.
Proceed with caution: possible threats of quality improvement
There is now abundant evidence that the quality of medical care in the United States is not 
nearly as high as desired and limited evidence suggests the same problem exists in pediatric 
IBD care. As momentum continues to build and further improvement work is initiated, it is 
imperative that pediatric gastroenterologists, improvement leaders, and other stakeholders 
pause to consider several pragmatic and methodological issues. First, it is essential to be 
mindful that not all quality improvement interventions are effective. There are numerous 
reports in the literature of negative QI studies, or studies that show moderate improvement at 
best. Furthermore, QI studies are typically not held to the same high standards as other 
clinical studies. Because randomized trials of QI interventions are uncommon, secular trends 
and/or co-interventions represent a major threat to the validity of published studies [97]. 
Given that quality improvement work often consumes a large amount of resources, including 
human capital, it is important to weigh the potential benefits of quality improvement against 
the costs involved and the alternative uses of these resources. Another consideration is that 
of unintended consequences of QI. For example, measuring and rewarding certain aspects of 
care may encourage those practices at the expense of other, non-measured but equally 
beneficial practices [98]. Other unintended consequences of QI may arise from changes in 
the organization of complex systems. These consequences, such as prescribing errors 
resulting from computer order entry, are often difficult to anticipate [97]. Despite these 
caveats, the upside for quality improvement work can be tremendous and the pay-offs can be 
seen over a relatively short period of time (5–10 years). When compared to the investment 
of resources, risk of failure, potential for harm, and time course required for the 
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development and testing of medical and/or surgical technologies, quality improvement 
appears to be a reasonable and necessary step in the effort to improve patient outcomes.
E. Conclusion
The future is bright for quality of care in the United States. After a half-century of slow 
progress, the quality of care movement was galvanized by two provocative IOM reports. 
Key stakeholders-providers, purchasers, and the public-have emerged and are shaping the 
landscape of quality improvement. Momentum and experience using QI methodology 
(multi-center collaboration, adaptation of the chronic care model, information technology 
interventions, and public reporting) to improve patient outcomes are growing in a number of 
primary care and subspecialty settings, most notably cystic fibrosis. As a consequence, 
pediatric gastroenterologists will have opportunities (and perhaps some pressure) to use 
similar strategies to assess and improve the care delivered to children with IBD. Quality 
improvement in pediatric IBD faces a number of unique challenges which will require 
thoughtful consideration by all stakeholders. Nevertheless, pediatric gastroenterologists have 
the obligation to patients and the profession to embrace these challenges.
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Figure 1. The chronic care model
The chronic care model, a useful framework for delivery system design, posits that 
improved patient outcomes are the result of carefully designed and coordinated systems of 
care that include patient and family self-management support, delivery system design, 
decision support, and clinical information systems working in concert with the greater health 
care organization and community resources.
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Figure 2. The Model for Improvement
The Model for Improvement describes a stepwise process for process improvement. Time-
sensitive and measurable aims are established, quantitative measures are developed to 
determine whether specific changes lead to improvement, and changes that are most likely 
to result in improvement are identified. Changes are then tested on a small scale using the 
Plan-Do-Study-Act (PDSA) cycle-planning interventions, trying them, observing the results, 
and acting on what is learned.
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Table 1
Methods of Measuring Health Care Quality
Structure Process Outcome
Definition Characteristics of the setting in which 
the care is delivered.
Indicate what steps health care providers 
took in the care of an individual patient.
Change in a patient’s current/ 
future health status that can be 
attributed to antecedent health care
Examples 1 Nurse to patient ratio
2 Use of electronic medical 
record system
3 Practice type
4 Level of accreditation
1 Timely prescription of 
medications
2 Ordering appropriate screening 
exams, monitoring for 
medication toxicity
1 Disease activity 
assessment
2 Quality of life
3 Functional status
Advantages 1 Easiest to measure
2 Reflect attributes of the 
health system as an entire 
unit
3 Indicate opportunities for 
system re-design
1 Direct measure of care
2 Can be condition specific
3 Can reflect evidence-based care
4 Measurable in a timely manner
5 May influence actual practice 
(P4P as example)
1 Intrinsically the most 
meaningful quality 
indicator (to patients 
and providers)
Disadvantages 1 Do not measure care at 
the level of the individual 
patient
2 Relatively weak 
association with patient 
outcomes
1 Costly to develop and collect
2 Often do not reflect 
comprehensive care
3 May encourage over-utilization
4 Rely in documentation of 
services performed which may 
not be in clinical records.
1 Factors outside of the 




2 Often a long time must 
elapse before outcomes 
occur
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Table 2
Reasons for Variation in Care
Type of
Variation
Definition and types Examples
Warranted 1 Variation due to characteristics of the illness 
itself (disease type, severity, phenotype, etc).
2 Variation driven by patient/family preferences.
- Use of budesonide in mild to moderate ileal 
Crohn's disease but not in pancolitis
- Use of enteral feeding as induction therapy in a 
patient/family who prefers NG feeds to 
corticosteroid side effects
Unwarranted 1 Variation in effective care and patient safety—
failure to provide care consistent with evidence 
based practices (underuse) or medical errors 
(misuse)
2 Variation in preference-sensitive care—failure 
to incorporate patient/family preference in 
decisions in which two medically acceptable 
options exist
3 Variation in supply-sensitive care—variation in 
healthcare utilization driven by the per capita 
quantity of healthcare resources (overuse)
Failure to perform TB screening prior to initiation of 
biologics
Inappropriate medication dosing; failure to consider 
drug interactions
Failure to involve patient/families in selection of 
maintenance therapy
Greater frequency of MRI imaging in hospitals with 
more scanners and/or radiologists with body imaging 
expertise in IBD
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